The University of Texas Southwestern Medical Center at Dallas

1. Merck Sharp & Dohme Corporation $2,193,878 329 payments
2. Regeneron Pharmaceuticals, Inc. $1,432,263 769 payments
3. Genentech, Inc. $538,638 67 payments
4. GlaxoSmithKline, LLC. $469,895 116 payments
5. Daiichi Sankyo Inc. $441,418 113 payments
6. Grifols Shared Services North America, Inc. $271,057 9 payments
7. Pfizer Inc. $261,141 60 payments
8. Aveo Pharmaceuticals, Inc. $208,751 20 payments
9. CSL Behring $190,869 46 payments
10. Exelixis Inc. $92,808 4 payments

1. A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma $944,202 429 payments
2. A Phase II Study of Pembrolizumab and Bavituximab in Patients with Advanced Hepatocellular Carcinoma $469,440 7 payments
3. Phii Il22fc Anti St2 in Severe Covid 19 Pneumonia $401,293 47 payments
4. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy $279,990 13 payments
5. A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC $248,482 22 payments
6. A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy $194,872 7 payments
7. Ds8201-A-U301 $188,110 32 payments
8. A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy $178,273 273 payments
9. A Phase 1b/2, Open-Label, Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma $171,088 8 payments
10. A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients $165,150 31 payments

1. Other $15,531 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.